Lung Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_28_3600 - Biologically Effective Dose and the Tumor Control in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: Comparison of Isocenter- and PTV-Based Prescription Methods

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Biologically Effective Dose and the Tumor Control in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: Comparison of Isocenter- and PTV-Based Prescription Methods
T. Ikawa, K. Wada, N. Kanayama, T. Hirata, M. Isono, S. Ohira, Y. Ueda, M. Miyazaki, M. Morimoto, K. Konishi, and T. Teshima; Osaka International Cancer Institute, Osaka, Japan

Purpose/Objective(s): Isocenter-based prescription method in stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) is the most widely used technique in Japan. Lately, however, it has been replaced by PTV-based prescription method to ensure PTV coverage. The aim of this study is to evaluate the impact of the biologically effective dose (BED) on the clinical outcomes by making a comparison between Isocenter- and PTV-based prescription methods.

Materials/Methods: We retrospectively reviewed patients with early-stage NSCLC (≤5 cm in diameter) who underwent SBRT at our institution from January 2010 to December 2016 and received follow-up of at least 6 months. A total dose of 48 Gy in four fractions was prescribed at the isocenter from 2010 to 2013 (Isocenter group), while that was prescribed to cover 95% of planning target volume (PTV D95) from 2014 to 2016 (PTV group). ITV was determined by using 4D-CT scan as the volume encompassing GTVs in all respiratory phases. PTV was generated from ITV with 5-8 mm margins in all directions. Local control (LC) was analyzed using Kaplan-Meier method and Cox proportional hazard model.

Results: A total of 152 patients and 154 tumors was included (Icocenter group: 92 patients and 93 tumors, PTV group: 60 patients and 61 tumors). The median calculated BEDs10 of the PTV D95 and the ITV D99 for the Isocenter group were 87.0 Gy (range, 57.4-97.2 Gy) and 91.4 Gy (76.7-101.4 Gy), respectively. For the PTV group, the corresponding doses were 105.6 Gy (105.6-105.6 Gy) and 149.1 Gy (114.8-157.6 Gy), respectively. Median follow-up periods for all tumors were 42 months (range, 6-90 months) in the Isocenter group and 23 months (6-41 months) in the PTV group. The 2-year LC rates were 84.5% in the Isocenter group and 95.8% in the PTV group (log-rank test, p = 0.105). In multivariate analysis adjusting for gender, histologic subtype, tumor size and BED, BED10 of PTV D95 (>105 Gy versus ≤105 Gy; HR, 3.10; 95% CI, 0.074-1.00; p = 0.049) and histologic subtype (SqCC versus Others; HR, 4.89; 95% CI, 1.91-12.43; p = 0.0013) were identified as independent predictive factors for LC. After stratification by tumor size, the PTV group (BED10 of PTV D95 >105 Gy) had better local control for tumors more than 2 cm in diameter compared with the Isocenter group (BED10 of PTV D95 ≤105 Gy) (2-year LC rate, 100% versus 75.9%; p = 0.030), while the difference was not significant for tumors 2 cm or less in diameter (2-year LC rate, 91.3% versus 92.8%; p = 0.87).

Conclusion: BED10 of PTV D95 >105 Gy is associated with improvement of local control for tumors more than 2 cm. PTV-based prescription method with 48 Gy in four fractions to cover PTV D95 showed excellent 2-year local control, although longer follow-up is needed to evaluate the long-term outcome.

Author Disclosure: T. Ikawa: None. K. Wada: None. N. Kanayama: None. T. Hirata: None. K. Konishi: None.

Send Email for Toshiki Ikawa


Assets

TU_28_3600 - Biologically Effective Dose and the Tumor Control in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: Comparison of Isocenter- and PTV-Based Prescription Methods



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Biologically Effective Dose and the Tumor Control in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: Comparison of Isocenter- and PTV-Based Prescription Methods